Alterity Therapeutics appointed Phillip Hains as its CFO, effective Jan. 31, 2024.

Hains, formerly the company secretary of Alterity since 2014, will replace Kathryn Andrews, who resigned to pursue other interests but will continue to support the company during the transition.

Alterity Therapeutics specialises in developing disease-modifying treatments for neurodegenerative diseases with its lead asset, ATH434, currently being evaluated in two Phase 2 clinical trials in multiple system atrophy.